Login / Signup

Assessment of Dasatinib Versus Nilotinib as Upfront Therapy for Chronic Phase of Chronic Myeloid Leukemia in Qatar: A Cost-Effectiveness Analysis.

Ahmad AdelDina AbushanabAnas HamadMohammad AbdullaMohamed IzhamMohamad A Yassin
Published in: Cancer control : journal of the Moffitt Cancer Center (2021)
Upfront therapy of chronic myeloid leukemia-chronic phase patients by nilotinib plan appears to be more cost-effective than dasatinib.
Keyphrases
  • chronic myeloid leukemia
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • peritoneal dialysis
  • prognostic factors
  • stem cells
  • drug induced
  • patient reported